Sign Out
Hypersensitivity to cabergoline, any other component of the product, or any ergot alkaloid.
History of pulmonary, pericardial and retroperitoneal fibrotic disorders (See Fibrosis/Valvulopathy under Precautions).
Long-term treatment: Anatomical evidence of cardiac valvulopathy of any valve as determined by pre-treatment echocardiogram showing valve leaflet thickening, valve restriction, valve mixed restriction-stenosis (See Fibrosis/Valvulopathy under Precautions).
